Pasithea Therapeutics Warrants
KTTAW
5 hedge funds and large institutions have $108K invested in Pasithea Therapeutics Warrants in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
61% less capital invested
Capital invested by funds: $278K → $108K (-$170K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.73K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$1.41K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$100 |
Top Sellers
KTTAW Hedge Fund Activity: Q2 2022 in Review
5 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q2 2022, worth a combined $108K — down 61% from $278K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new KTTAW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.73K.
- 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q2 2022, up from 4 in Q1 2022.
- Funds reported $108K of Pasithea Therapeutics Warrants stock for Q2 2022, down 61% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics Warrants positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics Warrants buyer in Q2 2022 was Susquehanna International Group, an estimated $1.73K added.
Based on aggregated 13F filings for Q2 2022.